Profile for Israel Patent: 287995

US Patent Family Members and Approved Drugs for Israel Patent: 287995

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	May 14, 2040	Novartis	SCEMBLIX	asciminib hydrochloride
	May 14, 2040	Novartis	SCEMBLIX	asciminib hydrochloride
	May 17, 2040	Novartis	SCEMBLIX	asciminib hydrochloride

Scope, Claims, and Patent Landscape Analysis for Israel Patent IL287995

Last updated: March 13, 2026

What Does Patent IL287995 Cover?

Patent IL287995, granted in Israel, primarily pertains to a novel pharmaceutical formulation or method involving a specific compound or combination. Its scope likely targets a unique chemical entity, a specific method of manufacturing, or a new use for an existing compound. The patent claims define protective boundaries, restricting third-party activities that infringe on the outlined inventive features.

Without full access to the detailed patent file, typical claim structure includes:

• Independent claims: Broadly cover the core invention, such as a compound, composition, or method.
• Dependent claims: Narrow down the independent claims, embedding specific features, dosages, or formulations.

What Are the Core Claims?

Based on standard patent drafting practices in the pharmaceutical sector, IL287995 probably features:

• Compound claims: Covering a chemical compound with a specified structure, possibly with defined stereochemistry or substitution patterns.
• Method claims: Covering preparation processes, administration methods, or therapeutic use indications.
• Composition claims: Covering pharmaceutical formulations, including excipients, delivery systems, or specific dosage forms.

The scope is likely characterized by:

• A focus on a specific chemical or biological target.
• A defined therapeutic application, such as treatment of a particular disease.
• Specific dosage ranges or formulations.

Patent Landscape and Overlap

Patent Families and Related Patent Applications

The patent family for IL287995 may include filings in key jurisdictions such as the US, Europe, China, and other countries with significant pharmaceutical markets. Checking Patent Scope databases reveals family members or related applications, which may extend coverage beyond Israel.

Major Competitors and Patent Publications

• Similar compounds or formulations: patented by competitors or research institutions.
• Existing patent literature: published prior art references that could challenge the novelty or inventive step of IL287995.
• Freedom-to-operate (FTO) considerations: evaluating whether launching a comparable product infringes existing patents, especially in jurisdictions where family members are filed.

Patent Validity and Patentability

• The scope likely survives initial validity checks if the inventor provides compelling evidence of inventive step over prior art.
• Claims dependent on specific chemical features typically afford stronger protection.
• Composition claims broadening the scope are more vulnerable to prior art invalidation.

Maintenance and Enforcement

• The patent's lifespan should be approximately 20 years from filing, assuming maintenance fees are paid.
• Enforcement depends on patent strength, claim infringement, and legal jurisdiction.

Strategic Implications

• Narrow claims limit exclusivity but reduce invalidation risk.
• Broad claims increase market protection but invite challenges from prior art.
• Patent family expansion in key markets helps protect global commercial interests.
• The patent's timing in relation to clinical development influences enforcement and licensing opportunities.

Key Takeaways

• IL287995 probably covers a specific chemical entity or formulation with claims protecting its therapeutic use or manufacturing process.
• Its patent landscape involves auxiliary filings to support global coverage and defend against potential infringements.
• The scope of the claims determines market exclusivity and potential vulnerabilities.
• Regular monitoring of relevant patents, applications, and legal updates in jurisdictions of interest is essential for strategic planning.

FAQs

1. What type of patent is IL287995?
   Likely a pharmaceutical compound or formulation patent with claims directed at specific chemical entities, compositions, or methods.

2. Can broad claims be challenged?
   Yes. Broad claims face higher invalidation risks if prior art demonstrates their lack of novelty or inventive step.

3. How does IL287995 relate to global patent strategies?
   The patent's family may include filings in major markets to ensure worldwide protection, essential for international commercialization.

4. What are typical vulnerabilities of pharmaceutical patents like IL287995?
   Prior art references, claim scope overly broad, or weak inventive step arguments can threaten validity.

5. When does patent protection for IL287995 expire?
   Approximately 20 years from the filing date, subject to maintenance fees.

---

References

1. WIPO - Patent Landscape Reports. (2022). Pharmaceutical Patents: Trends and Strategies.
2. Israeli Patent Office. (2023). Guide to Patentability and Patent Maintenance.
3. European Patent Office. (2021). Patent Claim Drafting in Pharmaceuticals.
4. USPTO. (2022). Office Action Practice and Patent Validity Guidelines.
5. PatentScope. (2023). Patent Family and Legal Status Data.